Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

Androgen-deprivation therapy (ADT) historically represented the milestone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Recently, combining androgen receptor-targeted agents (ARTA) or docetaxel with ADT significantly improved clinical outcomes in this setting. The efficacy of the combined use of an ARTA with docetaxel and ADT (triplet), however, was unknown, and often conflicting data derived from subgroup analysis of randomized phase III trials. In order to better define the benefits and risks of the triplet in mHSPC, we carried out a systematic review and meta-analysis of available clinical trials.

Methods

A literature search with no data restriction using Medline/PubMed, the Cochrane Library, and American Society of Clinical Oncolog

SUBMITTER: Maiorano BA 

PROVIDER: S-EPMC9588886 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature